Once-weekly 12-week (3HP) tuberculosis prevention options for people living with HIV
Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options Trial
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA-IRVINE · NIH-11378911
This work compares two ways of delivering a 12-week once-weekly TB prevention medicine (3HP) to people living with HIV to help more people finish treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA-IRVINE (nih funded) |
| Locations | 1 site (IRVINE, UNITED STATES) |
| Trial ID | NIH-11378911 on ClinicalTrials.gov |
What this research studies
If you have HIV and are offered 3HP to prevent tuberculosis, this compares a simplified 'facilitated' self-care plan to routine self-care. The simplified plan adds enhanced counseling, automated phone reminders that check for side effects, and 99DOTS-style medication packaging that lets clinics monitor adherence. People at multiple HIV clinics are enrolled and randomly assigned to one approach or the other, and staff track who completes the 12 weekly doses and any adverse events. The project also measures cost and how easy each approach is to use in routine clinic settings.
Who could benefit from this research
Good fit: Adults living with HIV who are eligible for 3HP preventive therapy and do not have active tuberculosis are the ideal candidates.
Not a fit: People with active TB, those not eligible for 3HP, or individuals without access to a participating clinic or phone-based reminders may not benefit.
Why it matters
Potential benefit: If successful, this could increase completion of TB preventive therapy and reduce TB illness among people living with HIV.
How similar studies have performed: A prior randomized trial in Uganda found facilitated self-administered 3HP reached 92% completion and was preferred, so the approach has promising prior evidence but needs wider testing.
Where this research is happening
IRVINE, UNITED STATES
- UNIVERSITY OF CALIFORNIA-IRVINE — IRVINE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CATTAMANCHI, ADITHYA — UNIVERSITY OF CALIFORNIA-IRVINE
- Study coordinator: CATTAMANCHI, ADITHYA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Syndrome Virus